Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 8/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862784 | 0.88 | NR1H3 (0.37) | NR1H2NR1H3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL23992542 | 0.83 | KIF11 (0.37) | NR1H2NR1H3CDK8 | |
| SCHEMBL20059347 | 0.79 | P2RX4 (0.40) | NR1H2NR1H3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL16449484 | 0.78 | NPC1 (0.41) | NR1H2NR1H3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL20059322 | 0.78 | NR1H3 (0.34) | NR1H2NR1H3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL13864781 | 0.78 | NR1H2 (0.35) | NR1H2NR1H3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1573992 | 0.78 | P2RX4 (0.47) | NPSR1P2RX4 | |
| SCHEMBL29406608 | 0.78 | P2RX4 (0.47) | NPSR1P2RX4 | |
| SCHEMBL29379993 | 0.78 | P2RX4 (0.47) | NPSR1P2RX4 | |
| SCHEMBL13203012 | 0.77 | P2RX4 (0.43) | MAPTSMN1; SMN2NPSR1P2RX4CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12041848-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, NR2E3 | NR1H2 634/4885NR1H3 681/4885MAPT 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.